bioRxiv Preprint: Novel ‘Post-Loading’ Strategy for RNA into Empty Lipid Nanoparticles Solves Cold Chain Challenges

bioRxiv USA

Overview

A bioRxiv preprint introduces a novel ‘post-loading’ strategy for RNA into lipid nanoparticle (LNP) carriers. This method allows empty LNPs to be manufactured and stored separately, with RNA loaded just prior to administration. The technology aims to overcome traditional mRNA-LNP cold chain storage limitations, improving vaccine access and adaptability to new mRNA sequences. Post-loaded LNPs demonstrated equivalent intracellular delivery efficiency and internal structure to conventional co-precipitation LNPs, potentially revolutionizing mRNA medicine logistics and accessibility.

In Depth

Key Findings: New ‘Post-Loading’ Strategy for RNA into LNPs Addresses Storage and Accessibility Challenges for mRNA Medicines

A preprint article published on bioRxiv proposes an innovative ‘post-loading’ strategy for incorporating RNA into lipid nanoparticle (LNP) carriers. This groundbreaking method allows for the pre-manufacture and separate storage of empty LNPs, with RNA loaded just prior to use. This technology holds the potential to solve the long-standing challenge of cold chain storage for mRNA medicines, dramatically improving global access to vaccines and gene therapies.

Technical and Clinical Details: Manufacturing and Storing Empty LNPs, and Just-in-Time RNA Loading

Traditional mRNA-LNP formulations are typically manufactured using co-precipitation methods, where mRNA and lipid nanoparticles are formed simultaneously. The resulting complexes require ultra-cold storage (cold chain) to maintain mRNA stability. However, these cold chain requirements have been a significant barrier to distribution and accessibility, particularly in developing countries. The proposed ‘post-loading’ strategy involves the following processes:

• Manufacturing and Storage of Empty LNPs: First, empty LNPs, which do not contain RNA, are manufactured. These empty LNPs are expected to be relatively stable and suitable for long-term storage under refrigerated or ambient conditions. This would significantly reduce logistics costs and infrastructure burden.
• Just-in-Time RNA Loading: At the point of care, the stored empty LNPs are loaded with the desired mRNA sequence. This process is designed to be rapid and simple, allowing for flexible responses in medical settings.

The preprint demonstrated experimentally that post-loaded LNPs exhibited ‘equivalent intracellular delivery efficiency and internal structure’ compared to LNPs manufactured by the conventional co-precipitation method. This suggests that the new method can solve storage and distribution challenges without compromising drug efficacy. The success of the post-loading technology relies on precise engineering of LNP composition and the loading process, considering many complex factors related to mRNA medicine stability, efficacy, and safety.

Background and Industry Context: Cold Chain Barrier to Global Deployment of mRNA Medicines

mRNA medicines gained global attention for their rapid development capabilities and high efficacy during the COVID-19 pandemic. However, the distribution of mRNA-LNP vaccines heavily relied on cold chains requiring ultra-low temperature storage and transport, which restricted access, particularly in low- and middle-income countries. The post-loading strategy could be a crucial solution to break down this cold chain barrier and deliver mRNA medicines to a wider range of regions. Furthermore, the flexibility to rapidly change mRNA sequences and load them into existing LNP carriers during emergencies or outbreaks of new pathogens is a significant advantage.Future Outlook: Contribution to Global Health and Widespread Adoption of mRNA Medicines

The RNA post-loading technology into LNPs holds the potential to fundamentally transform the future of mRNA medicines. If this technology is further refined and becomes applicable for large-scale production, global distribution of mRNA vaccines and gene therapies will become significantly easier, contributing to life-saving interventions, especially in regions with limited medical resources. Future research will focus on further validating the long-term stability of post-loaded LNPs, scaling up manufacturing processes, and their applicability to diverse mRNA payloads. This technology is expected to play a crucial role in accelerating pandemic responses, expanding access to rare disease treatments, and realizing personalized medicine.

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.

• Your email and selected fields are used only to deliver the newsletter.
• We never share your information with third parties.
• You can unsubscribe anytime via the link in each email.

See our Privacy Policy for details.

Agree & Continue ▶

Takes about a minute · Unsubscribe anytime